Femtobiomed Inc
327610
Company Profile
Business description
Femtobiomed Inc is a South Korea based company engaged in developing a cargo-free intracellular delivery platform called Cell Shot Platform. It is focused on using this technology to work on cell-based therapeutic pipelines.
Contact
17 Pangyo-ro 228 (ibaegisippal) beo
Sampyeong-dong, Bundang-gu, Gyeonggi-do
Seongnam-si13487
KORT: +82 316228501
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.70 | 41.30 | 0.46% |
| CAC 40 | 8,123.88 | 27.50 | -0.34% |
| DAX 40 | 24,308.44 | 20.04 | 0.08% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,858.13 | 39.29 | -0.40% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 50,402.39 | 895.18 | 1.81% |
| NZX 50 Index | 13,508.30 | 174.90 | 1.31% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,699.90 | 39.70 | 0.46% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |